Honours

Awards

• ‘Professor Anupam Sengupta Memorial Medal’ for academic excellence in Pharmaceutical Chemistry in M. Pharm awarded by Jadavpur University, India (2006).
• ‘Best Oral Presentation Award of ICCE, Thailand’ in International Congress of Chemistry and Environment Conference (ICCE) at Ubonrathchathani, Thailand (2010).
• National Doctoral Fellowship (NDF) awarded by All India Council for Technical Education (AICTE), India (2009).
• UGC Research Fellowship in Science for Meritorious Students awarded by University Grant Commission (UGC), India (2008).
• UGC Scholarship for pursuing M. Pharm., awarded by University Grant Commission (UGC), India (2004).

Publications

• Development and validation of a high throughput LC-MS/MS method for simultaneous quantitation of pioglitazone and telmisartan in rat plasma and its application to a pharmacokinetic study. Journal of Pharmaceutical Analysis, 2017. 7; 381–387.
  Impact Factor: 14.026.
• Degradation kinetics and characterization of major degradants of binimetinib employing liquid chromatography-high resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 2022. 215, 114753.
  Impact Factor: 3.571.
• Critical strategies to pinpoint carryover problems in liquid chromatography-mass spectrometry: a systematic direction for their origin identification and mitigation. Microchemical Journal. 2022. 179, 107464.
  Impact Factor: 5.304.
• Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: A needful consideration towards modern anticancer drug discovery. Drug Metabolism Reviews. 2022, https://doi.org/10.1080/03602532.2022.2048007.
  Impact Factor: 6.984.
• Engineering immunity via skin-directed drug delivery devices. Journal of Controlled Release. 2022, 345, 385-404.
  Impact Factor: 11.467.
• A systematic UHPLC-Q-TOF-MS/MS based analytical approach for characterization of flibanserin metabolites and establishment of biotransformation pathway. Journal of Chromatography B, 2021, 1185, 123011.
  Impact Factor: 3.318.
• Biosimilars accessible in the market for the treatment of cancer. Journal of Controlled Release. 2021, 336, 112-129.
  Impact Factor: 11.467.
• A mechanistic explanation on degradation behavior of flibanserin for identification and characterization of its potential degradants using LC-DAD/ESI/APCI-Q-TOF-MS/MS. Microchemical Journal. 2021, 167, 106281.
  Impact Factor: 5.304.
• Identification and structural characterization of potential degraded impurities of ribociclib by time of flight -tandem mass spectrometry,and their toxicity prediction. Journal of Pharmaceutical and Biomedical Analysis. 2021, 197, 113933.
  Impact Factor: 3.571.
• LC-Q-TOF-MS driven identification of potential degradation impurities of venetoclax, mechanistic explanation on degradation pathway and establishment of a quantitative analytical assay method. Journal of Analytical Science and Technology, 2020. 11 (54),
  1-13. Impact Factor: 3.568.
• Target Specific Intracellular Quantification of Etoposide by Quadrupole-Time of Flight based Mass Spectroscopic Method. Journal of Chromatography B, 2020, 1152, 122233.
  Impact Factor: 3.318.
• Challenges and strategies for quantification of drugs in the brain: current scenario and future advancement. Critical Reviews in Analytical Chemistry, 2022, 52 (1), 93-105.
  Impact Factor: 5.686.
• Time of flight mass spectrometry based in vitro and in vivo metabolite profiling of ribociclib and their toxicity prediction. Journal of Chromatography B, 2020, 1147, 122142.
  Impact Factor: 3.318.
• Mass spectrometry based rapid quantitative bioanalysis of flibanserin; pharmacokinetic and brain tissue distribution study. Journal of Analytical Toxicology, 2020, 44 (6), 559–569.
  Impact Factor: 3.220.
• Amalgamation of Stress Degradation and Metabolite Profiling in Rat Urine and Feces for Characterization of Oxidative Metabolites of Flibanserin using UHPLCQ-TOF-MS/MS, H/D Exchange and NMR Technique. Journal of Chromatography B, 2020, 1139, 121993.
  Impact Factor: 3.318.
• Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products. International Journal of Pharmaceutics. 2020, 576, 119018.
  Impact Factor: 6.510.
• Advancement in analytical strategies for quantification of the multifaceted nitroxidative stress biomarker 3-Nitrotyrosine in biological matrices. Critical Reviews in Analytical Chemistry, 2020, 50 (3), 265-289.
  Impact Factor: 5.686.
• Establishment of a quantitative bioanalytical method for an acetylcholinesterase inhibitor Ethyl 3-(2-(4-fluorophenyl) amino)-4-phenylthiazol-5-yl)-3-oxopropanoate including its physicochemical characterization and in vitro metabolite profiling using Liquid
  Chromatography-Mass Spectrometry. Journal of Chromatography B, 2018. 1096; 214–222.
  Impact Factor: 3.318.
• Drug development and bioanalytical method validation for a novel anticancer molecule, 4-(Dimethylamino)-2-(p-tolylamino) thiazole-5-carbonitrile. Drug Development Research, 2018. 79, 391-399.
  Impact Factor: 5.004.
• Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review. International Journal of Pharmaceutics, 2018. 543 (1–2); 328-344.
  Impact Factor: 6.510.